SEC Form 4 · accession 0001209191-16-111235
Aimmune Therapeutics, Inc. · AIMT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owners
Patrick G Enright
10% Owner
Bakker Juliet Tammenoms
10% Owner
Longitude Venture Partners II, L.P.
10% Owner
Longitude Capital Partners II, LLC
10% Owner
Period of report
Mar 29, 2016
Accepted (ET)
Mar 31, 2016 · 4:59 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001631650
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, $0.0001 par valueF1,F2 | Mar 29, 2016 | P | 33,064 | $13.4986 | A | 7,467,694 | I | By Longitude Venture Partners II, L.P. |
| Common Stock, $0.0001 par valueF3,F2 | Mar 29, 2016 | P | 45,440 | $14.1465 | A | 7,513,134 | I | By Longitude Venture Partners II, L.P. |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Reflects purchases of ordinary shares executed in multiple transactions at prices ranging from $12.90 to $13.89. The price reported reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the purchases were effected.
- F2This report is filed jointly by Longitude Capital Partners II, LLC ("Longitude Capital II"), Longitude Venture Partners II, L.P. ("Longitude Venture II"), Patrick G. Enright ("Mr. Enright") and Juliet Tammenoms Bakker ("Ms. Bakker"), all of whom share beneficial ownership of more than 10% of the capital stock of the Issuer. Longitude Capital II as general partner of Longitude Venture II maybe deemed to have sole voting, investment and dispositive power over the shares held by Longitude Venture II. Mr. Enright and Ms. Bakker are each managing members of Longitude Capital II and in their capacity as such, may be deemed to exercise shared voting and investment power over the shares held by Reporting Persons. Each of Longitude Capital II, Mr. Enright and Ms. Bakker disclaims beneficial ownership of such shares except to the extent of its, his or her pecuniary interest therein.
- F3Reflects purchases of ordinary shares executed in multiple transactions at prices ranging from $13.90 to $14.29. The price reported reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the purchases were effected.